Paper Details

  1. Home
  2. Paper Details

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.

Author: Ballesta-LópezOctavio, Martínez-CuadrónDavid, Megías-VericatJuan Eduardo, MontesinosPau, Solana-AltabellaAntonio

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study focuses on the development of new treatments for Acute Myeloid Leukemia (AML), a type of blood cancer. About one-third of AML patients have a mutation in a gene called FLT3, which is a target for new drugs called tyrosine kinase inhibitors (TKIs). The study highlights the approval of several FLT3-targeting TKIs and the development of even more treatments like crenolanib.
Paper Details　
Original Abstract of the Article :
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in one-third of patients with Acute Myeloid Leukemia (AML). Midostaurin, quizartinib, and gilteritinib have been approved in the last years for the treatment of AML, and more Tyrosine Kinase Inhibitors (TKIs) targeting FLT3 are being developed su...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14728214.2021.2009800

データ提供：米国国立医学図書館（NLM）

FLT3 Inhibitors: A New Frontier in AML Treatment

Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow. This research explores the use of FLT3 inhibitors, a class of medications that target the FLT3 gene, in treating AML.

FLT3 Inhibitors: Targeting the Root of AML

The study highlights the development of FLT3 inhibitors, such as midostaurin, quizartinib, and gilteritinib, as promising new treatments for AML. These medications directly target the FLT3 gene, which is mutated in a significant proportion of AML patients, offering a highly targeted approach to treating this complex disease.

Hope for AML Patients: A New Era of Treatment

This research provides hope for individuals diagnosed with AML. The development of FLT3 inhibitors represents a significant advancement in our ability to treat this disease, offering patients new and effective options for managing their condition.

Dr.Camel's Conclusion

This research delves into the exciting world of FLT3 inhibitors, showcasing their potential to revolutionize AML treatment. The study's findings offer hope for a future where AML is a manageable, rather than a devastating, diagnosis.

Date :
  1. Date Completed 2022-04-05
  2. Date Revised 2022-06-07
Further Info :

Pubmed ID

35076348

DOI: Digital Object Identifier

10.1080/14728214.2021.2009800

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.